JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

Search

PROCEPT BioRobotics Corp

Chiusa

SettoreSettore sanitario

23.96 11.03

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.58

Massimo

25.97

Metriche Chiave

By Trading Economics

Entrata

-8.4M

-30M

Vendite

-6.9M

76M

Margine di Profitto

-39.073

Dipendenti

888

EBITDA

-2.9M

-22M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+52.93% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-158M

1.4B

Apertura precedente

12.93

Chiusura precedente

23.96

Notizie sul Sentiment di mercato

By Acuity

50%

50%

201 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

PROCEPT BioRobotics Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 23:53 UTC

Utili

Naver Posts Weaker First-Quarter Earnings

29 apr 2026, 23:41 UTC

Azioni calde

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr 2026, 23:55 UTC

Utili

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr 2026, 23:54 UTC

Utili

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr 2026, 23:52 UTC

Utili

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr 2026, 23:51 UTC

Utili

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr 2026, 23:51 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr 2026, 23:22 UTC

Utili

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr 2026, 23:22 UTC

Utili

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr 2026, 23:20 UTC

Utili

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr 2026, 23:20 UTC

Utili

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss Narrows>000002.SZ

29 apr 2026, 23:18 UTC

Utili

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr 2026, 23:17 UTC

Utili

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr 2026, 23:13 UTC

Utili

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr 2026, 23:12 UTC

Utili

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr 2026, 23:04 UTC

Utili

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr 2026, 23:04 UTC

Utili

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Confronto tra pari

Modifica del prezzo

PROCEPT BioRobotics Corp Previsione

Obiettivo di Prezzo

By TipRanks

52.93% in crescita

Previsioni per 12 mesi

Media 35.22 USD  52.93%

Alto 60 USD

Basso 20 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per PROCEPT BioRobotics Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

3

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

52.655 / 56.31Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

201 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
help-icon Live chat